Skip to content

Program notes — ASCO GU 2026

Internal working file — pre-meeting prep style (the style of asco-2026/program-notes.md), reconstructed post-meeting. Tracks, day-by-day shape, expected LBAs, discussant watch list, key dates. Status: post-meeting, 10 weeks out (today: May 11, 2026). Pre-embargo language preserved for fidelity to the working-notes style; speculative entries that were resolved on-the-day are flagged with the resolved value in italic.

Key dates

Date Event Notes
Jan 22, 2026 Abstract titles released 10:00 AM ET — included LBA titles (no body)
Feb 24, 2026 Regular abstract embargo lifts 5:00 PM ET — regular abstracts go public on the ASCO Meeting Library
Feb 26, 2026 (Thu) Day 1 — RCC LITESPARK-022 LBA418, LITESPARK-011 LBA417, CYTOSHRINK
Feb 27, 2026 (Fri) Day 2 — Urothelial / Bladder KEYNOTE-B15 LBA630 (headline). IMvigor011, NIAGARA biomarker, SunRISE-2
Feb 28, 2026 (Sat) Day 3 — Prostate PEACE-3 OS, PSMAaddition, MEVPRO-3, BRCAAway, CAPItello-281, ²²⁵Ac-PSMA
Mar 1, 2026 onward Post-meeting recap window ASCO Daily News dispatches; OncLive "Experts Recount" video stand-ups; trade-press preview-to-recap reconciliation pieces through April
May 11, 2026 (today) Vault scaffolding 10 weeks post-meeting; trial-page bulk-build now

Sources: ASCO GU Dates to Know, Roche/Genentech congress hub.

Venue + format

  • Venue: Moscone West, San Francisco, CA (the standard ASCO GU venue; co-located overflow at the Marriott Marquis for press / sponsor booths in prior years, varies year-to-year).
  • Attendance: ~3,500 total (in-person + virtual hybrid). Roughly 2,400 in-person + 1,100 virtual per ASCO registration patterns from prior years.
  • Format: 3 days, Thu–Sat. Hybrid (in-person + virtual). Co-sponsored by ASCO, ASTRO (American Society for Radiation Oncology), and SUO (Society of Urologic Oncology).
  • Daily theme structure: ASCO GU has historically organized days by disease group — Day 1 RCC, Day 2 urothelial/bladder, Day 3 prostate (the highest-volume group). 2026 followed the same pattern. ~3 oral abstract sessions + ~10 rapid-orals + multi-disciplinary panel discussions per day. ~1,200 abstracts total.
  • Plenary structure: Unlike ASCO main, ASCO GU does not have a dedicated single "Plenary Session" slot — instead, the LBAs are distributed across the disease-group days. LBA418 / LBA417 / LBA630 / PEACE-3 OS are the four practice-changing slots.

Day 1 — Thursday Feb 26 — Renal Cell Carcinoma

The RCC day was anchored by Merck's belzutifan franchise.

Slot Trial Drug / regimen Indication Status
LBA418 LITESPARK-022 Pembrolizumab + belzutifan vs pembro mono Adjuvant high-risk ccRCC post-nephrectomy DFS HR 0.72 (95% CI 0.59–0.87, p=0.0003) — practice-changing; sNDAs under FDA priority review at time of GU readout
LBA417 LITESPARK-011 Belzutifan + lenvatinib vs cabozantinib 2L+ mRCC (post-IO/TKI) Mixed PFS/OS readout per Motzer presentation; details to reconcile against abstract
Oral CYTOSHRINK SBRT + nivo/ipi vs nivo/ipi Metastatic RCC Exploratory neoantigen-release hypothesis
Posters / rapid ccRCC neoadjuvant cabo/nivo; non-clear-cell RCC subtypes — — Signal-generating

Day 2 — Friday Feb 27 — Urothelial / Bladder

The bladder day was anchored by EV+pembro perioperative MIBC. This was the headline of ASCO GU 2026 by news cycle.

Slot Trial Drug / regimen Indication Status
LBA630 KEYNOTE-B15 / EV-304 Enfortumab vedotin + pembrolizumab vs gem/cis Perioperative MIBC, cisplatin-eligible EFS HR 0.53 (95% CI 0.41–0.70, p<0.001); 24-mo OS 86.9% vs 81.3% — displaces cisplatin in curative-intent MIBC
Oral IMvigor011 ctDNA-guided atezolizumab vs observation Adjuvant MIBC, ctDNA+ Positive — establishes ctDNA-guided adjuvant as deployable
Oral NIAGARA biomarker analyses Durvalumab perioperative + biomarker Perioperative MIBC ctDNA dynamics sub-analysis
Oral SunRISE-2 Gemcitabine intravesical system + cetrelimab MIBC alternative to CRT Missed primary BI-EFS; signal-only CR rates
Rapid orals FGFR3 mUC (erdafitinib follow-ups, novel FGFR3 selective inhibitors); ADC sequencing post-EV — — Class read-through

Day 3 — Saturday Feb 28 — Prostate

The prostate day was the deepest — four-plus oral sessions across mHSPC, mCRPC, biomarker-selected populations, and radioligand therapy.

Slot Trial Drug / regimen Indication Status
Oral PEACE-3 / EORTC 1333 Enzalutamide + Ra-223 vs enza Bone-mets mCRPC 1L OS HR 0.76 (95% CI 0.60–0.96, one-sided p=0.0096) — re-validates alpha-emitter combo with modern bone protection. Follow-up to ESMO 2024 rPFS readout.
Oral PSMAaddition ¹⁷⁷Lu-PSMA-617 + ADT + ARPI vs ADT + ARPI 1L mHSPC Positive rPFS per topline — moves RLT from 3L+ (VISION) to 1L mHSPC. OS mature follow-up at ASCO main / ESMO 2026.
Oral MEVPRO-3 Mevrometostat (EZH2i) + enzalutamide mCRPC Ph3 interim; Ph1 had shown rPFS 14.3 vs 6.2 mo
Oral BRCAAway Olaparib + abiraterone (upfront combo vs sequential) HRR-altered mCRPC Tests upfront combo vs sequential PARPi/ARPI
Oral CAPItello-281 Capivasertib + abi vs placebo + abi PTEN-deficient mHSPC Positive per topline; PRO assessments emphasized — first PTEN-biomarker-selected Ph3 in mHSPC
Oral ²²⁵Ac-PSMA first-in-human Actinium-225 PSMA dose-escalation mCRPC (post-¹⁷⁷Lu-PSMA salvage) Fred Saad presenting; signal-generating alpha-emitter

Discussant watch list

ASCO GU discussant identity is signal-rich; the disease-group seniors typically frame the post-meeting narrative.

  • Prostate (PEACE-3 OS, PSMAaddition, CAPItello-281): likely Karim Fizazi (Gustave Roussy), Stephen Freedland (Cedars-Sinai), Tanya Dorff (City of Hope), Fred Saad (Université de Montréal — also a presenter for ²²⁵Ac-PSMA). The mHSPC vs mCRPC line-of-therapy framing is the recurring question.
  • RCC (LITESPARK-022 / LITESPARK-011): likely Robert J. Motzer (MSK — also a presenter), Toni Choueiri (Dana-Farber), David McDermott (Beth Israel Deaconess). HIF-2α + IO sequencing is the framing.
  • Bladder (KEYNOTE-B15 / EV-304): likely Matthew Galsky (Mount Sinai), Thomas Powles (Barts), Andrea Apolo (NCI). The "cisplatin displacement" framing dominated the post-meeting cycle.
  • Rare GU (penile / testicular / adrenal): smaller disease-group seniors — Curtis Pettaway (MDACC, penile), Lance Pagliaro (Mayo Clinic, testicular).

Forward-looking flags

ASCO GU readouts typically chain into one of:

  1. ASCO 2026 main meeting (May 29 – Jun 2):
  2. PROTEUS LBA1 (apalutamide perioperative HRLPC) — the ASCO main Plenary GU sibling to ASCO GU's prostate slate. PROTEUS covers the localized / perioperative space; ASCO GU 2026 covered mHSPC + mCRPC.
  3. KEYNOTE-B15 / EV-304 OS-mature update expected.
  4. PEACE-3 bone-mets subgroup follow-up.

  5. LITESPARK-022 OS interim.

  6. ESMO 2026 (Oct 23 – 27): typical venue for OS-mature follow-up of GU trials whose primary DFS / PFS endpoint hit at GU. PSMAaddition OS mature; CAPItello-281 OS mature.

  7. SUO 2026 (Dec): surgical-oncology perspective on perioperative MIBC and prostate trials. Cystectomy outcomes follow-up for KEYNOTE-B15.

  8. AUA 2027 (May): urology perspective; NCCN guideline reconciliation likely complete by then.

What's speculative vs. confirmed (post-meeting)

Confirmed (from public coverage; to be reconciled against ASCO Meeting Library abstract): - Meeting dates, venue, format (asco.org/gu; medically.gene.com) - LITESPARK-022 DFS HR 0.72 (Merck press release, post-meeting trade-press confirmation) - KEYNOTE-B15 / EV-304 EFS HR 0.53; 24-mo OS 86.9% vs 81.3% (Merck + Pfizer/Astellas press releases) - PEACE-3 OS HR 0.76 (EORTC press release; OncLive recap) - LBA abstract numbers (LBA418, LBA417, LBA630)

Speculative — pending Meeting Library reconciliation: - LITESPARK-011 exact PFS / OS numbers (trade press reports "mixed"; abstract permalink needed) - PSMAaddition full headline numbers (positive topline; OS interim only) - MEVPRO-3 Ph3 interim numbers (only Ph1 numbers in public coverage so far) - BRCAAway PFS magnitude - CAPItello-281 PRO endpoints - ²²⁵Ac-PSMA dose-escalation safety / activity details - Named discussants (above watch list — to confirm against the official program archive) - Rare-GU rapid-orals (InPACT, testicular, adrenal)

Dead ends (for now)

  • Full discussant transcripts / slide decks: ASCO GU does not pre-release slides; only available via ASCO Virtual (paid registration) or post-presentation press coverage.
  • OS-mature data for ASCO GU 2026 positive trials: by definition, not yet available. Forward-looking flags above.
  • NCCN guideline reconciliation: typically 60–90 days post-meeting; some updates already in place by May 11, 2026 (KEYNOTE-B15 / EV-304 perioperative MIBC anticipated in NCCN bladder update; LITESPARK-022 anticipated in NCCN kidney update following sNDA action).

Sources